NIAGEN BIOSCIENCE INC (NAGE) Stock Fundamental Analysis
USA - NASDAQ:NAGE - US1710774076 - Common Stock
6.84 USD
+0.24 (+3.64%)
6.9979 USD
+0.16 (+2.31%)
Overall NAGE gets a fundamental rating of 6 out of 10. We evaluated NAGE against 58 industry peers in the Life Sciences Tools & Services industry. While NAGE has a great health rating, its profitability is only average at the moment. NAGE is not overvalued while it is showing excellent growth. This is an interesting combination. This makes NAGE very considerable for growth investing!
1. Profitability
1.1 Basic Checks
NAGE had positive earnings in the past year.
In the past year NAGE had a positive cash flow from operations.
NAGE had negative earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: NAGE reported negative operating cash flow in multiple years.
1.2 Ratios
NAGE has a Return On Assets of 19.37%. This is amongst the best in the industry. NAGE outperforms 94.83% of its industry peers.
Looking at the Return On Equity, with a value of 27.62%, NAGE belongs to the top of the industry, outperforming 93.10% of the companies in the same industry.
With an excellent Return On Invested Capital value of 19.03%, NAGE belongs to the best of the industry, outperforming 93.10% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 19.37% | ||
| ROE | 27.62% | ||
| ROIC | 19.03% |
ROA(3y)-9.02%
ROA(5y)-25.18%
ROE(3y)-18.83%
ROE(5y)-52.67%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
NAGE has a better Profit Margin (15.24%) than 86.21% of its industry peers.
NAGE has a Operating Margin of 14.33%. This is in the better half of the industry: NAGE outperforms 79.31% of its industry peers.
The Gross Margin of NAGE (63.62%) is better than 84.48% of its industry peers.
NAGE's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 14.33% | ||
| PM (TTM) | 15.24% | ||
| GM | 63.62% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y2.12%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so NAGE is creating value.
Compared to 1 year ago, NAGE has more shares outstanding
Compared to 5 years ago, NAGE has more shares outstanding
Compared to 1 year ago, NAGE has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 12.04 indicates that NAGE is not in any danger for bankruptcy at the moment.
The Altman-Z score of NAGE (12.04) is better than 96.55% of its industry peers.
NAGE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 12.04 |
ROIC/WACC1.81
WACC10.5%
2.3 Liquidity
NAGE has a Current Ratio of 3.88. This indicates that NAGE is financially healthy and has no problem in meeting its short term obligations.
NAGE has a Current ratio of 3.88. This is in the better half of the industry: NAGE outperforms 65.52% of its industry peers.
A Quick Ratio of 3.24 indicates that NAGE has no problem at all paying its short term obligations.
With a decent Quick ratio value of 3.24, NAGE is doing good in the industry, outperforming 63.79% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.88 | ||
| Quick Ratio | 3.24 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 2300.00% over the past year.
NAGE shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 19.18%.
Measured over the past years, NAGE shows a quite strong growth in Revenue. The Revenue has been growing by 16.56% on average per year.
EPS 1Y (TTM)2300%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%150%
Revenue 1Y (TTM)19.18%
Revenue growth 3Y13.87%
Revenue growth 5Y16.56%
Sales Q2Q%32.86%
3.2 Future
Based on estimates for the next years, NAGE will show a very strong growth in Earnings Per Share. The EPS will grow by 45.98% on average per year.
NAGE is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 22.77% yearly.
EPS Next Y46.88%
EPS Next 2Y65.95%
EPS Next 3Y45.98%
EPS Next 5YN/A
Revenue Next Year30.1%
Revenue Next 2Y25.23%
Revenue Next 3Y22.77%
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 28.50, NAGE can be considered very expensive at the moment.
NAGE's Price/Earnings ratio is a bit cheaper when compared to the industry. NAGE is cheaper than 72.41% of the companies in the same industry.
NAGE is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 26.06, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 24.84, NAGE is valued on the expensive side.
Based on the Price/Forward Earnings ratio, NAGE is valued a bit cheaper than the industry average as 75.86% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 32.73, NAGE is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 28.5 | ||
| Fwd PE | 24.84 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, NAGE is valued a bit cheaper than the industry average as 62.07% of the companies are valued more expensively.
77.59% of the companies in the same industry are more expensive than NAGE, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 26.06 | ||
| EV/EBITDA | 27.8 |
4.3 Compensation for Growth
NAGE's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
NAGE has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as NAGE's earnings are expected to grow with 45.98% in the coming years.
PEG (NY)0.61
PEG (5Y)N/A
EPS Next 2Y65.95%
EPS Next 3Y45.98%
5. Dividend
5.1 Amount
NAGE does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
6.84
+0.24 (+3.64%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners37.48%
Inst Owner ChangeN/A
Ins Owners0.01%
Ins Owner Change0%
Market Cap545.49M
Revenue(TTM)99.60M
Net Income(TTM)17.73M
Analysts85.45
Price Target16.36 (139.18%)
Short Float %7.93%
Short Ratio4.08
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)216.49%
Min EPS beat(2)180.11%
Max EPS beat(2)252.87%
EPS beat(4)4
Avg EPS beat(4)315.75%
Min EPS beat(4)180.11%
Max EPS beat(4)488.82%
EPS beat(8)8
Avg EPS beat(8)196.75%
EPS beat(12)12
Avg EPS beat(12)140.83%
EPS beat(16)13
Avg EPS beat(16)103.25%
Revenue beat(2)2
Avg Revenue beat(2)8.99%
Min Revenue beat(2)7.71%
Max Revenue beat(2)10.27%
Revenue beat(4)4
Avg Revenue beat(4)7.72%
Min Revenue beat(4)6.07%
Max Revenue beat(4)10.27%
Revenue beat(8)4
Avg Revenue beat(8)1.25%
Revenue beat(12)6
Avg Revenue beat(12)1.27%
Revenue beat(16)6
Avg Revenue beat(16)-0.38%
PT rev (1m)0%
PT rev (3m)6.08%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-20%
EPS NY rev (1m)0%
EPS NY rev (3m)10.77%
Revenue NQ rev (1m)1.19%
Revenue NQ rev (3m)1.29%
Revenue NY rev (1m)0.47%
Revenue NY rev (3m)2.43%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 28.5 | ||
| Fwd PE | 24.84 | ||
| P/S | 4.69 | ||
| P/FCF | 26.06 | ||
| P/OCF | 25.72 | ||
| P/B | 8.5 | ||
| P/tB | 8.54 | ||
| EV/EBITDA | 27.8 |
EPS(TTM)0.24
EY3.51%
EPS(NY)0.28
Fwd EY4.03%
FCF(TTM)0.26
FCFY3.84%
OCF(TTM)0.27
OCFY3.89%
SpS1.46
BVpS0.8
TBVpS0.8
PEG (NY)0.61
PEG (5Y)N/A
Graham Number2.08
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 19.37% | ||
| ROE | 27.62% | ||
| ROCE | 24.09% | ||
| ROIC | 19.03% | ||
| ROICexc | 148.37% | ||
| ROICexgc | 153.27% | ||
| OM | 14.33% | ||
| PM (TTM) | 15.24% | ||
| GM | 63.62% | ||
| FCFM | 18% |
ROA(3y)-9.02%
ROA(5y)-25.18%
ROE(3y)-18.83%
ROE(5y)-52.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y2.12%
F-Score7
Asset Turnover1.27
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 35.42% | ||
| Cap/Sales | 0.24% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 121.54% | ||
| Profit Quality | 118.08% | ||
| Current Ratio | 3.88 | ||
| Quick Ratio | 3.24 | ||
| Altman-Z | 12.04 |
F-Score7
WACC10.5%
ROIC/WACC1.81
Cap/Depr(3y)21.85%
Cap/Depr(5y)22.95%
Cap/Sales(3y)0.27%
Cap/Sales(5y)0.33%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)2300%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%150%
EPS Next Y46.88%
EPS Next 2Y65.95%
EPS Next 3Y45.98%
EPS Next 5YN/A
Revenue 1Y (TTM)19.18%
Revenue growth 3Y13.87%
Revenue growth 5Y16.56%
Sales Q2Q%32.86%
Revenue Next Year30.1%
Revenue Next 2Y25.23%
Revenue Next 3Y22.77%
Revenue Next 5YN/A
EBIT growth 1Y823.21%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year776.03%
EBIT Next 3Y168.46%
EBIT Next 5YN/A
FCF growth 1Y1146.07%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y960.55%
OCF growth 3YN/A
OCF growth 5YN/A
NIAGEN BIOSCIENCE INC / NAGE FAQ
What is the fundamental rating for NAGE stock?
ChartMill assigns a fundamental rating of 6 / 10 to NAGE.
What is the valuation status for NAGE stock?
ChartMill assigns a valuation rating of 6 / 10 to NIAGEN BIOSCIENCE INC (NAGE). This can be considered as Fairly Valued.
What is the profitability of NAGE stock?
NIAGEN BIOSCIENCE INC (NAGE) has a profitability rating of 6 / 10.
What is the valuation of NIAGEN BIOSCIENCE INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for NIAGEN BIOSCIENCE INC (NAGE) is 28.5 and the Price/Book (PB) ratio is 8.5.